Implant Sciences' QS-B220 Explosives Trace Detector Receives "Designated" Status for SAFETY Act

Company's latest regulatory success provides important benefits for growing non-government customer base

Nov 07, 2013, 07:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., Nov. 7, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that the QS-B220 explosives and drugs trace detector has been issued a SAFETY Act Designation (as defined in Section 25.2 of the Regulations) from the Department of Homeland Security. The QS-H150 handheld explosive trace detector also holds a SAFETY Act Designation.

The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) was enacted as part of the Homeland Security Act of 2002. The SAFETY Act is intended to facilitate the development and deployment of effective anti-terrorism technologies by providing product liability protection. The Act creates liability limitations for claims arising out of, relating to, or resulting from an "Act of Terrorism" where Qualified Anti-Terrorism Technologies have been deployed.

Glenn D. Bolduc, Implant Sciences' President and CEO, stated, "SAFETY Act Designation is an important achievement, especially for our non-government customers. Coupled with our insurance coverage, the liability limitations built into the Act provide protection against lawsuits arising from the use of Implant Sciences' ETD equipment in defending against terrorism. We have had key accounts cite SAFETY Act Designation as one of their requirements for purchase and we anticipate that our receiving it will help us continue to build sales momentum for the QS-B220."

For more information about the SAFETY Act and the Department of Homeland Security's Designation under the Safety Act, please see

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. In addition to receiving TSA qualification, the QS-B220 has received STAC certification and a Qualified Anti-Terrorism Technology Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). Implant Sciences' QS-H150 handheld explosives trace detector has also received a Qualified Anti-Terrorism Technology Designation under the SAFETY Act. For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; our business is subject to intense competition; our markets are subject to rapid technology change and our success will depend on our ability to develop and introduce new products; we may not be able to retain our management and key employees or identify, hire and retain additional personnel as needed; we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.


Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO


Investor Contact:
Laurel Moody

SOURCE Implant Sciences Corporation